Published in Cancer Weekly, February 2nd, 2010
"We estimated the capability of surgical and non-surgical options to improve LC further in this disease," wrote D. Deruysscher and colleagues, University Medical Center.
The researchers concluded: "Eligible studies were phase III trials reporting 2-year survival data as well as the incidence of LC and/or distant metastases Effect estimates. as well as the statistical uncertainty of these, were combined in circlet to estimate the benefit in terms of LC from combining multiple modalities Results It was estimated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.